Net income per diluted share rose to $3.39, up from $3.01 in the year-ago quarter. Net operating income per diluted share increased to $3.43, compared to $3.07 in Q1 2025. Full-year 2026 earnings guidance was increased to a range of $15.40 to $15.90, representing a $0.35 midpoint increase. Total life net sales grew by 6%, while health net sales saw a significant 58% increase. The company repurchased 1.4 million shares for $203 million during the quarter.